These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23346156)

  • 1. Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?
    Shin H; Kim MH; Lee SJ; Lee KH; Kim MJ; Kim JS; Cho JW
    J Clin Neurol; 2013 Jan; 9(1):21-5. PubMed ID: 23346156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
    Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F
    Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
    Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
    Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
    Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A;
    Mov Disord; 2020 Apr; 35(4):606-615. PubMed ID: 31967355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.
    Sampedro F; Martínez-Horta S; Perez-Perez J; Horta-Barba A; Lopez-Mora DA; Camacho V; Fernández-León A; Gomez-Anson B; Carrió I; Kulisevsky J
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1111-1116. PubMed ID: 30627816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-onset Huntington's disease with 40-42 CAG expansion.
    Capiluppi E; Romano L; Rebora P; Nanetti L; Castaldo A; Gellera C; Mariotti C; Macerollo A; Cislaghi MG
    Neurol Sci; 2020 Apr; 41(4):869-876. PubMed ID: 31820322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
    Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D
    J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the Huntington's disease (IT15) protein product in HD patients.
    Schilling G; Sharp AH; Loev SJ; Wagster MV; Li SH; Stine OC; Ross CA
    Hum Mol Genet; 1995 Aug; 4(8):1365-71. PubMed ID: 7581375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.
    Paulsen JS; Long JD; Ross CA; Harrington DL; Erwin CJ; Williams JK; Westervelt HJ; Johnson HJ; Aylward EH; Zhang Y; Bockholt HJ; Barker RA;
    Lancet Neurol; 2014 Dec; 13(12):1193-201. PubMed ID: 25453459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural brain correlates of dementia in Huntington's disease.
    Martinez-Horta S; Sampedro F; Horta-Barba A; Perez-Perez J; Pagonabarraga J; Gomez-Anson B; Kulisevsky J
    Neuroimage Clin; 2020; 28():102415. PubMed ID: 32979842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.
    Rosas HD; Reuter M; Doros G; Lee SY; Triggs T; Malarick K; Fischl B; Salat DH; Hersch SM
    Mov Disord; 2011 Aug; 26(9):1691-7. PubMed ID: 21611979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAG repeat size and clinical presentation in Huntington's disease.
    Ashizawa T; Wong LJ; Richards CS; Caskey CT; Jankovic J
    Neurology; 1994 Jun; 44(6):1137-43. PubMed ID: 8208412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte telomere shortening in Huntington's disease.
    Scarabino D; Veneziano L; Peconi M; Frontali M; Mantuano E; Corbo RM
    J Neurol Sci; 2019 Jan; 396():25-29. PubMed ID: 30396032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin sensitivity and early-phase insulin secretion in normoglycemic Huntington's disease patients.
    Russo CV; Salvatore E; Saccà F; Tucci T; Rinaldi C; Sorrentino P; Massarelli M; Rossi F; Savastano S; Di Maio L; Filla A; Colao A; De Michele G
    J Huntingtons Dis; 2013; 2(4):501-7. PubMed ID: 25062734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT: an unexpected case of Huntington's disease.
    Michels S; Buchholz HG; Rosar F; Heinrich I; Hoffmann MA; Schweiger S; Tüscher O; Schreckenberger M
    BMC Neurol; 2019 May; 19(1):78. PubMed ID: 31043171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Imaging Markers to Track Huntington's Disease Pathology.
    Wilson H; De Micco R; Niccolini F; Politis M
    Front Neurol; 2017; 8():11. PubMed ID: 28194132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Widespread heterogeneous neuronal loss across the cerebral cortex in Huntington's disease.
    Nana AL; Kim EH; Thu DC; Oorschot DE; Tippett LJ; Hogg VM; Synek BJ; Roxburgh R; Waldvogel HJ; Faull RL
    J Huntingtons Dis; 2014; 3(1):45-64. PubMed ID: 25062764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.